Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction
Christopher Rush(University of Glasgow), Mark C. Petrie(Copenhagen University Hospital), Pardeep S. Jhund(Copenhagen University Hospital), Rhian M. Touyz(University of Ottawa), John J.V. McMurray(Western Infirmary), Margaret McEntegart(Golden Jubilee National Hospital), J. Paul Rocchiccioli(Golden Jubilee National Hospital), Colin Berry(University of Glasgow), Keith G. Oldroyd(Golden Jubilee National Hospital), Ross T. Campbell(University of Glasgow), Mitchell Lindsay(Golden Jubilee National Hospital), Thomas J. Ford(Golden Jubilee National Hospital), Ninian N. Lang(British Heart Foundation), Clare Murphy(Royal Alexandra Hospital), Novalia Sidik(University Hospitals Bristol NHS Foundation Trust)
Cited by 245
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k